Loading...

INSM INSMED INC Product Launches 8-K Filing

NSMD

NSM

INSMED INC

(INSM)

2024 8-K

EU Approval Granted

Financial Results Report

Financial Statements

Equity Offerings

Product Expansion

Debt-Equity Swaps

Financial Statements

Rights Offerings

Debt-Equity Swaps

Management Change

Financial Results

FDA Review Accepted

Investor Conference

Agreement Termination

Loan Agreement Update

Redemption of Notes

Financial Results Press Rel...

Regulation FD Disclosure

Redemption of Convertible S...

Notice from AstraZeneca

Webinar on Market Outlook

Underwriting Agreement

Positive Phase 3 results fo...

Approval of Amendment to In...

Financial Results and Safet...

Sales Agreement and Financi...

Regulation FD Disclosure

Financial Results Press Rel...

Financial Results Press Rel...

Annual Meeting and Approval...

Earnings Reports

Earnings Reports

Regulation FD Disclosure

External Links:

Insmed Inc announced positive results from its Phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis, with plans to file a New Drug Application with the FDA in Q4 2024.

AI Assistant

INSMED INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.